Nasdaq

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ...
Labroots

Mitigating ADC Toxicities With Linker-Payload Design

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
Business Wire

Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment

BEIJING & PRAGUE--(BUSINESS WIRE)--Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human ...
Morningstar

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...
FiercePharma

Samsung Biologics, LegoChem partner to propel ADC development and production

Samsung Biologics signed a partnership deal with LegoChem Biosciences focused on the development and production of antibody-drug conjugates (ADCs). Although financial details of the deal weren’t ...